BR0107404A - Derivados de indol que atuam como antagonistas do receptor mcp-1 - Google Patents

Derivados de indol que atuam como antagonistas do receptor mcp-1

Info

Publication number
BR0107404A
BR0107404A BR0107404-0A BR0107404A BR0107404A BR 0107404 A BR0107404 A BR 0107404A BR 0107404 A BR0107404 A BR 0107404A BR 0107404 A BR0107404 A BR 0107404A
Authority
BR
Brazil
Prior art keywords
hydrogen
mcp
halogen
act
receptor antagonists
Prior art date
Application number
BR0107404-0A
Other languages
English (en)
Inventor
Alan Wellington Faull
Jason Grant Kettle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0107404A publication Critical patent/BR0107404A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"DERIVADOS DE INDOL QUE ATUAM COMO ANTAGONISTAS DO RECEPTOR MCP-1"'. A presente invenção se refere a um composto de fórmula (I): em que: R^ 1^ é hidrogênio, halogênio ou metóxi; R^ 2^ é hidrogênio, halogênio, metila, etila ou metóxi; R^ 3^ é um grupo halo ou um grupo trifluorometila; R^ 4^ é um grupo halo ou um grupo trifluorometila; R^ 5^ é hidrogênio ou halogênio; R^ 6^ é hidrogênio ou halogênio; desde que quando R^ 5^ e R^ 6^ forem ambos hidrogênio, e um de R^ 3^ e R^ 4^ for cloro ou flúor, então o outro não será cloro nem flúor; ou um sal ou pró-droga farmaceuticamente aceitáveis dos mesmos. Esse compostos apresentam atividade útil no tratamento de doenças inflamatórias, especificamente ao antagonizar o efeito mediado pela MCP-1 em um animal de sangue quente, tal como o ser humano.
BR0107404-0A 2000-01-13 2001-01-11 Derivados de indol que atuam como antagonistas do receptor mcp-1 BR0107404A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0000626.2A GB0000626D0 (en) 2000-01-13 2000-01-13 Chemical compounds
PCT/GB2001/000069 WO2001051466A1 (en) 2000-01-13 2001-01-11 Indole derivatives as mcp-1 receptor antagonists

Publications (1)

Publication Number Publication Date
BR0107404A true BR0107404A (pt) 2002-10-08

Family

ID=9883551

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107404-0A BR0107404A (pt) 2000-01-13 2001-01-11 Derivados de indol que atuam como antagonistas do receptor mcp-1

Country Status (25)

Country Link
US (1) US20030144339A1 (pt)
EP (1) EP1252142A1 (pt)
JP (1) JP2003519683A (pt)
KR (1) KR20020064375A (pt)
CN (1) CN1395565A (pt)
AR (1) AR026839A1 (pt)
AU (1) AU780992B2 (pt)
BG (1) BG106894A (pt)
BR (1) BR0107404A (pt)
CA (1) CA2393592A1 (pt)
CO (1) CO5271703A1 (pt)
EE (1) EE200200394A (pt)
GB (1) GB0000626D0 (pt)
HK (1) HK1049486A1 (pt)
HU (1) HUP0300694A3 (pt)
IL (1) IL150272A0 (pt)
IS (1) IS6429A (pt)
MX (1) MXPA02006611A (pt)
NO (1) NO20023380L (pt)
NZ (1) NZ519312A (pt)
PL (1) PL356031A1 (pt)
RU (1) RU2002121636A (pt)
SK (1) SK10072002A3 (pt)
WO (1) WO2001051466A1 (pt)
ZA (1) ZA200204354B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
WO2004069809A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US8058320B2 (en) * 2004-09-13 2011-11-15 Kureha Corporation Thermally foamable microsphere, production method thereof, use thereof, composition containing the same, and article
DE602006010433D1 (de) 2005-12-09 2009-12-24 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
US7507736B2 (en) 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
CA2682354C (en) 2007-04-16 2016-12-13 Abbott Laboratories 7-nonsubstituted indole mcl-1 inhibitors
WO2023224981A1 (en) * 2022-05-17 2023-11-23 Inipharm, Inc. Hsd17b13 inhibitors and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529724A (en) * 1983-10-11 1985-07-16 Mcneilab, Inc. 6H-indolo[2,1-c][1,4]benzodiazepines and 12-oxo derivatives useful as antihypertensives
DE3907388A1 (de) * 1989-03-08 1990-09-13 Kali Chemie Pharma Gmbh Verfahren zur herstellung von indolcarbonsaeurederivaten
US5272145A (en) * 1989-08-22 1993-12-21 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
US5081145A (en) * 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
US5273980A (en) * 1991-09-30 1993-12-28 Merck Frosst Canada Inc. Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5190968A (en) * 1991-09-30 1993-03-02 Merck Frosst Canada, Inc. (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5290798A (en) * 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5308850A (en) * 1991-09-30 1994-05-03 Merck Frosst Canada, Inc. (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5389650A (en) * 1991-09-30 1995-02-14 Merck Frosst Canada, Inc. (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5288743A (en) * 1992-11-20 1994-02-22 Abbott Laboratories Indole carboxylate derivatives which inhibit leukotriene biosynthesis
US5852046A (en) * 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5686481A (en) * 1993-12-21 1997-11-11 Smithkline Beecham Corporation Endothelin receptor antagonists
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
US5684032A (en) * 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
JP2000507556A (ja) * 1996-03-28 2000-06-20 スミスクライン・ビーチャム・コーポレイション ケモカインのカルボン酸インドール阻害剤
WO1998006703A1 (en) * 1996-08-14 1998-02-19 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9803228D0 (en) * 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
GB9803226D0 (en) * 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
GB9902461D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
US20030144339A1 (en) 2003-07-31
RU2002121636A (ru) 2004-01-10
BG106894A (bg) 2003-04-30
IS6429A (is) 2002-06-19
AU2532401A (en) 2001-07-24
KR20020064375A (ko) 2002-08-07
NO20023380D0 (no) 2002-07-12
CA2393592A1 (en) 2001-07-19
IL150272A0 (en) 2002-12-01
AR026839A1 (es) 2003-02-26
EE200200394A (et) 2003-12-15
CN1395565A (zh) 2003-02-05
JP2003519683A (ja) 2003-06-24
AU780992B2 (en) 2005-04-28
GB0000626D0 (en) 2000-03-01
WO2001051466A1 (en) 2001-07-19
HK1049486A1 (zh) 2003-05-16
ZA200204354B (en) 2003-09-01
NZ519312A (en) 2004-04-30
EP1252142A1 (en) 2002-10-30
CO5271703A1 (es) 2003-04-30
PL356031A1 (en) 2004-06-14
HUP0300694A2 (hu) 2003-07-28
HUP0300694A3 (en) 2005-08-29
MXPA02006611A (es) 2002-09-30
SK10072002A3 (sk) 2003-06-03
NO20023380L (no) 2002-09-03

Similar Documents

Publication Publication Date Title
JO2372B1 (en) Source drugs of 4-phenylpyridine derivatives
MY138352A (en) Benzothiazole derivatives
NO20075134L (no) Bestemte substituerte amider, fremgangsmate for femstilling derav og anvendelse derav
ATE485265T1 (de) 5-substituierte-2-phenylaminobenzamide als mek- inhibitoren
JO2282B1 (en) Oxazole derivatives
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
DE60224172D1 (de) Formanilid-derivative als beta2-adrenorezeptor-agonisten
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20041631L (no) Piperazinderivater med CCR1 reseptor antagonist
MA29213B1 (fr) Quinolones a substitution macrolones - amino
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
GB0413087D0 (en) Therapeutic compounds
MX2007005199A (es) Indolizinas sustituidas y derivados como agentes del sistema nervioso central.
EP0915094A4 (en) MORPHINANE DERIVATIVES AND MEDICAL USE THEREOF
BR0107404A (pt) Derivados de indol que atuam como antagonistas do receptor mcp-1
DE60031686D1 (de) Pyrazinone, diese verbindungen enthaltende zusammenstellungen
ATE318266T1 (de) 3-substituierte chinolin-4- carbonsäureamidderivate als nk-3- und nk-2- rezeptorantagonisten
EA201170150A1 (ru) Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона
MA30540B1 (fr) Derives de quinolines et compositions pharmaceutiques de ces derives.
TW200700390A (en) Metabolites for nk-1 antagonists for emesis
DE60225195D1 (de) Flavaxat-derivate als muscarin-rezeptor antagonisten
ATE239722T1 (de) Benzofurylpiperazine als serotonin-agonisten
IL160082A0 (en) Quinoline derivatives and use thereof as antitumor agents

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009.